The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only. Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test. Up to 3,000 participants will be enrolled in this study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
3,000
41 pancreatic cancer predisposition genes will be tested through a saliva-based swab
Chirurgia generale e del Pancreas Azienda Ospedaliera Universitaria Integrata
Verona, Italy
RECRUITINGPresence - absence of predisposing mutations
Prevalence of genetic mutations over the total tested
Time frame: 5 years
Correlation of genetic mutations with personal oncological history
Correlation between presence of predisposing mutation and prevalence of cancers
Time frame: 5 years
Correlation of genetic mutations with familial oncological history
Correlation between presence of predisposing mutation and prevalence of cancers in the family
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.